Erschienen in:
02.06.2020 | COVID-19 | Original Communication
Zur Zeit gratis
COVID-19 in teriflunomide-treated patients with multiple sclerosis
verfasst von:
Amir Hadi Maghzi, Maria K. Houtchens, Paolo Preziosa, Carolina Ionete, Biljana D. Beretich, James M. Stankiewicz, Shahamat Tauhid, Ann Cabot, Idanis Berriosmorales, Tamara H. W. Schwartz, Jacob A. Sloane, Mark S. Freedman, Massimo Filippi, Howard L. Weiner, Rohit Bakshi
Erschienen in:
Journal of Neurology
|
Ausgabe 10/2020
Einloggen, um Zugang zu erhalten
Abstract
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.